• Company
• K-Pharma wins another patent dispute against ‘Entresto’
• by Kim, Jin-Gu Apr 11, 2024 05:45am

• Policy
• Clopidogrel recall due to 1 CMO…’no issue escalation’
• by Lee, Hye-Kyung Apr 11, 2024 05:44am

• Company
• SK’s CMO business posted KRW 812 billion last year…
• by Chon, Seung-Hyun Apr 11, 2024 05:44am

• Company
• NIP vaccine Vaxneuvance lands in ‘Big 5’ hospitals in KOR
• by Eo, Yun-Ho Apr 11, 2024 05:44am

• Policy
• 4th-generation, 3 chamber IV nutrition receives reimb
• by Lee, Tak-Sun Apr 11, 2024 05:44am

• Company
• Mundipharma Korea closes its opioid analgesics business
• by Son, Hyung-Min Apr 9, 2024 05:50am

• Policy
• Approval of Beyfortus imminent in Korea
• by Lee, Hye-Kyung Apr 9, 2024 05:50am

• Company
• Korean and global pharmas in race for lung cancer drugs
• by Son, Hyung-Min Apr 9, 2024 05:50am

• Opinion
• [Reporter’s View] Delays in reimbursement listing
• by Lee, Tak-Sun Apr 9, 2024 05:50am

• Company
• Ilaris reimb passes DREC review, but again with a condition
• by Eo, Yun-Ho Apr 9, 2024 05:50am